Mid-Dermal Elastolysis (middermal elastolysis, elastolysis mediodermalis)
Mid-dermal elastolysis (MDE, middermal elastolysis, elastolysis mediodermalis)
Are You Confident of the Diagnosis?
Characteristic findings on physical examination
Mid-dermal elastolysis (MDE), first described by Shelley & Wood in 1977, is a skin condition of the elastic tissue predominantly manifesting on the trunk and proximal extremities. Most commonly observed skin changes include patches of well-circumscribed fine wrinkles (type I) and/or perifollicular papular protusions (type II,
Abdomen of a young female with severe MDE.
Expected results of diagnostic studies
The critical histopathologic feature of MDE is the selective loss of elastic fibers in the mid-dermis. Further histopathologic findings of MDE include mild dermal lymphohistiocytic infiltrates, elastophagocytosis of elastic fibers, and occasionally multinucleate giant cells. Special stains that accentuate elastic fibers may be helpful in making the diagnosis (
Ddecreased elastic fiber content in the mid-dermis of a young female with MDE (EvG staining).
Differential diagnoses include anetoderma, annular elastolytic giant cell granuloma, cutis laxa, and pseudoxanthoma elasticum-like papillary dermal elastolysis.
Who is at Risk for Developing this Disease?
MDE is a rare acquired skin condition. Up to 2010, about 80 cases of MDE have been reported in the medical literature. MDE usually affects Caucasian females at a median age of about 40 years. Pregnancy, intake of contraceptives, smoking and increased ultraviolet exposure have frequently been associated with the occurrence of MDE. Preexisting and/or associated skin conditions such as urticaria, atopic dermatitis, granuloma annulare, and phototoxic dermatitis have been described in MDE patients.
What is the Cause of the Disease?
The precise pathogenesis of MDE is unclear. Increased activity of elastases (matrix metalloproteinases, cathepsin G etc.) seems to result in elastin degradation. An altered elastin re-synthesis system may also be a causative factor of permanent elastic fiber loss in MDE.2-5
Systemic Implications and Complications
MDE was observed to be associated with systemic conditions such as Hashimoto’s thyroiditis, Graves disease, lupus erythematosus, Sweet syndrome and autoimmune phenomena (eg, elevated antinuclear antibodies). However, these conditions are likely coincidental in MDE.
There are no proved treatment options for patients with MDE. Anecdotically, topical tretinoin or dapsone led to some improvement of MDE.
Optimal Therapeutic Approach for this Disease
So far, there is no optimal therapeutic approach for patients with MDE. Because of the likely coincidental association with other autoimmune conditions, a specific workup for these disorders (autoimmune thyroid disease, lupus, etc.) is not necessary unless there are other clinical features of these disorders.
The patient should be informed that MDE is noninherited and of benign nature, though the condition may cause significant cosmetic and psychological impairment. The condition usually takes a chronic course. Ultraviolet overexposure and smoking should be avoided. Consultation with a psychologist and or psychiatrist may help with psychosocial issues.
Unusual Clinical Scenarios to Consider in Patient Management
MDE has been observed to be associated with systemic conditions such as Hashimoto’s thyroiditis, Graves’ disease, lupus erythematosus, Sweet syndrome and autoimmune phenomena (eg, elevated antinuclear antibodies). However, these conditions are likely coincidental in MDE.
What is the Evidence?
Shelley, WB, Wood, MG. "Wrinkles due to idiopathic loss of mid-dermal elastic tissue". Br J Dermatol. vol. 97. 1977. pp. 441-5.(First report on MDE in the world literature.)
Gambichler, T. "Mid-dermal elastolysis revisited". Arch Dermatol Res. vol. 302. 2010. pp. 85-93.(Comprehensive analysis of MDE cases previously reported in the literature.)
Patroi, I, Annessi, G, Girolomoni, G. "Mid-dermal elastolysis: a clinical, histologic, and immunohistochemical study of 11 patients". J Am Acad Dermatol. vol. 48. 2003. pp. 846-51.(So far, largest case series of MDE patients, including immunohistological studies.)
Gambichler, T, Stücker, M, Kreuter, A, Matip, R, Gaifullina, R, Scola, N. "Expression of extracellular matrix proteins in reticular variant of mid-dermal elastolysis". J Eur Acad Dermatol Venereol. vol. 24. 2010. pp. 1481-84.(Extensive sudies on a patient with MDE using immunohistochemistry and real-time RT-PCR.)
Lewis, KG, Bercovitch, L, Dill, SW, Robinson-Bostom, L. "Acquired disorders of elastic tissue: part II". decreased elastic tissue. J Am Acad Dermatol. vol. 51. 2004. pp. 165-85.(Comprehensive review on acquired diseases of the elastic tissue characterized by loss of elastic fibers such as MDE, anetoderma, annular elastolytic giant cell granuloma etc.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC